Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research presented today at the 52nd Annual Meeting of the American Society of Hematology (Orlando, December 4 – 7, 2010) provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), and how a new gene target functions…
ContinueAdded by Peter Hofland, PhD on December 4, 2010 at 9:30pm — No Comments
Added by Peter Hofland, PhD on October 22, 2010 at 4:30pm — No Comments
Added by Peter Hofland, PhD on June 5, 2010 at 11:30am — No Comments
2013
2012
2011
2010
2009
2008
2007
2005
2004
2001
© 2013 Created by Peter Hofland, PhD.
